

Please add new claims 38 and 39 as follows:

38. (New) A formula comprising active xanthine oxidoreductase (XOR), wherein said formula feed is in the form of a powder and is for administration to a human infant as a breast-milk substitute.

C3

39. (New) A formula feed comprising active xanthine oxidoreductase (XOR), wherein said formula feed is for administration to a human infant as a breast milk substitute and is nutritionally complete.

Remarks

Applicants respectfully request entry of this amendment because it does not raise issues that require further search or that have not been previously considered. Claims 1-18, 32, 35, and 38-39 remain pending after entry of this office action. Claims 19-31, 33, 34, 36, and 37 were cancelled herein. Claims 38-39 were added herein. Claims 1, and 11 have been amended herein. The amendments were made to more fully clarify the subject matter and have not added new subject matter. Favorable reconsideration is respectfully requested in light of the above amendments and the comments offered herein.

The Examiner rejected claim 11 under 35 U.S.C. § 112, second paragraph. Applicants respectfully traverse this rejection.

The Examiner rejected claims 33-34 under 35 U.S.C. § 102(b) as being anticipated by Bjorck et al. Applicants respectfully traverse this rejection.

The Examiner rejected claims 1, 7-8, 11, 15, and 33-34 under 35 U.S.C. § 102(b) as being anticipated by Cooray et al. Applicants respectfully traverse this rejection.

The Examiner rejected claims 1-4, 6-11, 14-17, and 33-34 under 35 U.S.C. § 102(b) as being anticipated by Clark et al. Applicants respectfully traverse this rejection.

The Examiner rejected claims 1-17 and 33-34 under 35 U.S.C. § 102(b) as being anticipated by Ho et al. Applicants respectfully traverse this rejection.

The Examiner rejected claims 33-34 under 35 U.S.C. § 102(b) as being anticipated by Zikakis. Applicants respectfully traverse this rejection.

The Examiner rejected claims 33-34 under 35 U.S.C. § 102(b) as being anticipated by Antrim et al. Applicants respectfully traverse this rejection.